Skip to main content

Advertisement

SpringerLink
Log in

Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the bone mineral density (BMD) in patients with early rheumatoid arthritis (RA) prior to and 6 months after adding low-dose corticosteroid (CS) treatment. Adult patients (>21 years old) with early RA (symptom duration <1 year) and severe joint pain under maximal dose of nonsteroidal anti-inflammatory drugs (NSAIDS) were started on low-dose prednisone (10 mg/day). Patients were evaluated after 1, 3, and 6 months. Disease activity measures including swollen and tender joint count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were documented, and the dose of prednisone was adjusted according to the level of pain at each visit. BMD of the femoral neck (FN) and lumbar spine (LS) was measured using dual energy X-ray absorptiometry prior to and 6 months after starting CS treatment. Calcium supplements, vitamin D, bisphosphonates, or hormonal therapy that may affect BMD were not permitted during the study. Twenty patients were eligible and 16 completed the study; 75% were female. The mean age was 47.2±12 years and mean duration of symptoms was 7±2 months. The mean BMD at the FN prior to and 6 months after starting CS treatment were 0.8080 g/cm2±0.1145 and 0.8242 g/cm2±0.1122, respectively (p=0.04). The mean BMD at the LS prior to and 6 months after starting CS treatment were 0.9429 g/cm2±0.1406 and 0.9490 g/cm2±0.1277, respectively (p=0.423). There was a significant correlation between the mean change of BMD at the FN and mean change of tender joint count (p=0.01), ESR (p=0.008), and CRP (p=0.006) but not with swollen joint count (p=0.099). However, there was no correlation between the change of BMD at the FN or LS and the change of any of the disease activity measures of every patient. Also, no correlation was seen between the cumulative dose of CS and the change in BMD. BMD increases significantly at the FN in early RA patients 6 months after adding low-dose CS to the treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Suzuki Y, Mizushima Y (1997) Osteoporosis in rheumatoid arthritis. Osteoporos Int 7 [Suppl 3]:s217

  2. Cortet B, Guyot MH, Solau E, Pigny P, Dumoulin F, Flipo RM et al (2000) Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol 18:683–690

    CAS  PubMed  Google Scholar 

  3. Cortet B, Flipo RM, Pigny P, Duquesnoy B, Boersma A, Marchandise X et al (1998) Is bone turnover a determinant of bone mass in rheumatoid arthritis? J Rheumatol 2339–2344

  4. Sinigaglia L, Nervitte A, Mela Q, Biacnhi G, Del Puenti A, Di Munno O et al (2000) A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. J Rheumatol 27:2582–2589

    CAS  PubMed  Google Scholar 

  5. Hansen M, Floresco A, Stoltenberg M, Podenphant J, Pedersen-Zbinden B, Horslev-Petersen K et al (1996) Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity and corticosteroid treatment. Scand J Rheumatol 25:367–376

    CAS  PubMed  Google Scholar 

  6. Lane NE, Pressman AR, Star V, Cummings SR, Nevitt MC (1995) Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 10:257–263

    CAS  PubMed  Google Scholar 

  7. Olbricht T, Benker G (1993) Glucocorticoid-induced osteoporosis: pathogenesis, and treatment, with special regard to the rheumatic disease. J Intern Med 234:237–244

    CAS  PubMed  Google Scholar 

  8. Felder M, Ruegsegger P (1991) Bone loss in patients with rheumatoid arthritis—effect of steroids measured by low dose quantitative computed tomography. Rheumatol Int 1:41–44

    Google Scholar 

  9. Koizumi K, Uchiyama G, Araki T, Hihara T, Ogata H, Monzawa S et al (1990) Fundamental evaluation of bone densitometry using dual energy X-ray absorptiometry (DEXA). Nippon Igaku Hoshasen Gakkai Zasshi 50:123–129

    CAS  PubMed  Google Scholar 

  10. Barthe N, Braillon P, Ducassou D, Basse-Cathalinat B (1997) Comparison of two Hologic DXA systems (QDR 1000 and QDR 4500/A). Br J Radiol 70:728–739

    Google Scholar 

  11. Roodman GD (1993) Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 53 [Suppl 1]:S94–S98

    Google Scholar 

  12. Toyoda T, Inokychi S, Saito S, Horie Y, Tomita S (1996) Bone loss of the radius in rheumatoid arthritis. Comparison between 34 patients and 40 controls. Acta Orthop Scand 67:269–273

    CAS  PubMed  Google Scholar 

  13. Brennan I, Chantry D, Jackson A, Maini R, Feldman M (1989) Inhibitory effect of TNF-alpha antibodies on synovial cell IL-1 production in rheumatoid arthritis. Lancet 2:244–247

    Article  CAS  PubMed  Google Scholar 

  14. Roux S, Orcel P (2000) Bone loss. Factors that regulate osteoclast differentiation: an update. Arthritis Res 6:451–456

    Article  Google Scholar 

  15. Tsoubi M, Kawakami A, Nakashima T, Matsuoka N, Urayama S, Kawabe Y (1999) Tumor necrosis factor-alpha and interleukin-1 beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 222–231

  16. Lee SW, Tsou AP, Chan H et al (1988) Glucocorticoids selectively inhibit the transcription of the interleukin 1β gene and decrease the stability of interleukin 1β mRNA. Proc Nat Acad Sci 85:1204–1208

    CAS  PubMed  Google Scholar 

  17. Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H et al (1995) Methotrexate action in rheumatoid arthritis; stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 34:602–609

    CAS  PubMed  Google Scholar 

  18. Cranney AB, McKendry RJ, Wells GA et al (2001) The effect of low dose methotrexate on bone density. J Rheumatol 28:2395–2399

    CAS  PubMed  Google Scholar 

  19. Mazzantini M, Di-Munno O, Incerti-Vecchi L, Pasero G (2000) Vertebral bone mineral density changes in female rheumatoid arthritis patients treated with low-dose methotrexate. Clin Exp Rheumatol 18:327–331

    CAS  PubMed  Google Scholar 

  20. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1997) Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 24:1489–1494

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Clinic, Nazareth Hospital, Nazareth, Israel

    George S. Habib

  2. Department of Medicine B, Carmel Medical Center, School of Medicine, Technion-Israel Institute of Technology, 7 Michal Street, 34362, Haifa, Israel

    George S. Habib

  3. Department of Medicine, Nazareth Hospital, Nazareth, Israel

    Shehadeh Haj

Authors
  1. George S. Habib
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shehadeh Haj
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George S. Habib.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Habib, G.S., Haj, S. Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. Clin Rheumatol 24, 129–133 (2005). https://doi.org/10.1007/s10067-004-0989-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-004-0989-1

Keywords

Search

Navigation